Article PDF first page preview

First page of Signet Ring Cell Carcinoma of the Stomach with Chylous Pleural Effusion: Laterality Shift and Fluid Composition Change

Introduction: Chylothorax is a rare manifestation of malignant pleural effusion, with gastric cancer accounting for only a small percentage of cases. Signet ring cell carcinoma (SRCC) is an aggressive tumor subtype that frequently invades the lymphatic system, leading to early dissemination. Case Presentation: A 66-year-old woman presented with bilateral chylothorax that was initially suspected to be a lymphoma. After a transient resolution, the pleural effusion returned on the left side, with a shift from chylous to non-chylous fluid and an increase in carcinoembryonic antigen levels. Despite endoscopic findings resembling early-stage gastric cancer, cytology confirmed SRCC. Despite treatment with capecitabine plus oxaliplatin and nivolumab, the disease progressed, resulting in bilateral effusion recurrence and death within 4 months. Genetic analysis revealed CLDN18.2 positivity. Conclusion: This case is unique because it demonstrates a rare progression from bilateral to unilateral pleural effusion, accompanied by a transition in pleural fluid characteristics, which has not been previously reported. The observations suggest dynamic changes in lymphatic obstruction and tumor infiltration. Early molecular profiling, which includes CLDN18.2 testing, may provide new opportunities for targeted therapy in aggressive gastric cancer cases.

Journal Section:
Case Report
This content is only available via PDF.
The Author(s). Published by S. Karger AG, Basel
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License .
Attribution-NonCommercial